Gait Analysis Parameter and Upper Limb Evaluation in Adult Patients With Neurological or Metabolic Pathology

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorCentre Hospitalier Universitaire de Liege

About this trial

The ActiLiège-Adult study is a prospective, longitudinal, observational study designed to collect natural history data on adult patients with neurological or metabolic diseases affecting movement. Conducted at the Centre de Référence Liégeois des Maladies Neuromusculaires in Liège, Belgium, the study will enroll 300 ambulant patients, including individuals with neuromuscular disorders and obesity. Using the Syde® wearable device, the study aims to continuously monitor motor function in real-life settings over a period of up to two years. The primary objective is to evaluate the utility of digital mobility outcomes, such as the 95th centile of stride velocity (SV95C), as reliable and objective endpoints for future clinical trials.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Ambulant patients (i.e. able to walk 10 meters without assistance)

Confirmed diagnosis by the investigator based on current gold standard in his/her disease (genetic testing, clinical criteria, etc.)

Myotonic dystrophy type 1 (DM1) and Charcot-Marie-Tooth (CMT) patients should present sensitive of motor signs on physical examination.

Myasthenic patients should be seropositive, and Myasthenia Gravis Foundation of America (MGFA) class II to IV.

Disqualifiers

Non-ambulant patients

Patients with extreme cognitive disorders that limit their understanding of the exercises to be performed

Patients who have undergone a surgical procedure or who have experienced recent trauma (within fewer than 6 months) affecting the upper or lower limbs

A concomitant chronic or acute neurological, endocrine, infectious, allergic, or inflammatory pathology within the 3-week period immediately prior to inclusion

Trial design

Design model

Parallel

Treatments tested in this trial

  • Syde

    Device

    Syde is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.

  • Dynamometric measurements of muscle strength

    Diagnostic test

    Dynamometric measurements of the maximum force of the following functions will be taken with the MyoTools: palmar grip (MyoGrip) and thumb-index pinch (MyoPinch). Test will be realized on the dominant side. Patients will be encouraged during the test. They will be given three trials and the best score will be entered.

  • The 6-minute walk test (6MWT)

    Diagnostic test

    This test consists of covering the greatest possible distance within 6 minutes, walking back and forth along a 25-meter hallway. The subject may stop if they need to. The evaluator will record the elapsed time after each half-lap, and the final distance that was covered at the end of the test. No help will be allowed during the test.

  • The 10-meter test (10MWT)

    Diagnostic test

    During this test, the subject must cover a distance of 10 meters as rapidly as possible. This test will be performed 3 times. The participant will be allowed to rest for one minute after the first and second instances of the test. No help will be allowed during the test.

  • The 4 stair-climbing test (4SC)

    Diagnostic test

    This is a standardized test during which the subject must climb the 4 stair steps as rapidly as possible. This test will be performed 3 times. The participant will be allowed to rest for one minute after the first and second instances of the test, or more if needed.

  • Test of rising from the floor (TRF)

    Diagnostic test

    This is a standardized test during which the subject must rise from the floor as rapidly as possible. The test starts with the participant lying on their back. This test will be performed 3 times. The participant will be allowed to rest for one minute after the first and second instances of the test.

  • The Timed up and go test (TUG)

    Diagnostic test

    During this standardized test, the subject is observed and timed while he/she rises from a chair, walks 3 meters, performs a 180° turn, walk back toward the chair and sits down.

  • The Progressive Supranuclear Palsy Rating Scale (PSP-RS)

    Diagnostic test

    This 28-item clinician-rated scale assesses motor and non-motor symptom severity in patients with PSP, with a score ranging from 0 (normal) to 100.

  • The Montreal Cognitive Assessment (MOCA)

    Diagnostic test

    The MOCA was designed as a rapid screening instrument for mild cognitive dysfunction. It assesses different cognitive domains: attention and concentration, executive function, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation. Scores on the MOCA range from 0 to 30, with higher score being better outcome.

  • The Charcot-Marie-Tooth examination score (CMTES)

    Diagnostic test

    The CMTES is a 28-point composite score that rates the patient's symptoms and signs. It is part of the Charcot-Marie-Tooth (CMT) neuropathy score and has been validated as a reproducible measure of disability in CMT. Higher scores indicate more severe neuropathy.

  • 9-Hole Peg Test (9-HPT)

    Diagnostic test

    The 9-HPT is a quantitative test of upper limb function. It is the second component of the Multiple Sclerosis Functional Composite (MSFC). The patient sits at a table with a shallow container containing nine sticks and a wooden or plastic block containing nine empty holes. When a timer is started, the patient places the nine sticks one after the other as quickly as possible into the nine holes and, once they are all in the holes, removes them as quickly as possible. The total time taken to complete the task is recorded. Two consecutive attempts with the dominant hand are immediately followed by two consecutive attempts with the non-dominant hand.

  • The Unified Huntington's Disease Rating Scale (UHDRS)

    Diagnostic test

    This 74-item clinical rating scale assesses patient performance and capacity in 4 domains: motor function, cognitive function, behavioral abnormalities, and functional capacity.

  • Quantitative Myasthenia Gravis (QMG)

    Diagnostic test

    The QMG is a clinician-rated 13-item scale used to quantify disease severity in patients with MG. The scale grades each domain (ocular, bulbar, respiratory, and limb function), with a total score ranging from 0 to 39 (lower score indicating a better clinical outcome).

  • The Myasthenia Gravis Activities of Daily Living Scale (MG-ADL)

    Diagnostic test

    This is an 8-item patient-reported scale assessing MG symptoms and their effects on daily activities. The score ranges from 0 to 24, with higher score indicating a worse clinical outcome.

  • The Scale for the Assessment and Rating of Ataxia (SARA)

    Diagnostic test

    This 8-item scale was developed to assess ataxia severity and disease progression. It evaluates gait and balance, speech, and upper and lower limb coordination. The score ranges from 0 to 40, with higher score indicating a worse clinical outcome.

  • Patient's Global Impression of Change (PGIC)

    Other intervention

    PGIC is a patient-reported scale used to assess how a patient feels their condition has changed over time. It typically uses a 7-point scale to capture the patient's overall perception of improvement in symptoms, function, and quality of life.

Treatment groups

300 Participants
are divided into 8 treatment groups

8

Treatment groups

See each treatment group below.

Group A: Neuromuscular condition - Muscle diseaseExperimental treatment 6 interventions
Group B: Neuromuscular condition - NeuropathyExperimental treatment 9 interventions
Group C: AtaxiaExperimental treatment 8 interventions
Group D: Huntington disease (HD) and HD-likeExperimental treatment 7 interventions
Group E: Progressive supranuclear palsy (PSP) and PSP-likeExperimental treatment 9 interventions
Group F: Spastic paraplesia and conditions where spasticity predominates, incl. strokeExperimental treatment 6 interventions
Group G: Obese patientsExperimental treatment 6 interventions
Group H: Neuromuscular condition - Neuromuscular JunctionExperimental treatment 8 interventions

Trial outcomes

Primary outcomes

1

95th Centile of Stride Velocity (SV95C)

Change in SV95C as measured by the Syde® wearable device, used to assess ambulatory function in real-life settings.

Time frame
Every 6 months for up to 2 years

Secondary outcomes

1

Device Acceptability and Adherence

Measures of user engagement with the Syde® device over time, including total recording time, valid days (≥5 hours), and time to reach 50 and 180 hours.

Time frame
Over 2 years
2

Correlation between Syde® and 6MWT

Correlation between the Syde digital variable and results from the 6-minute walk test (6MWT)

Time frame
Every 6 months for up to 2 years
3

Correlation between Syde® and 10MWT

Correlation between the Syde digital variable and results from the 10-meter test (10MWT)

Time frame
Every 6 months for up to 2 years
4

Correlation between Syde® and 4SC

Correlation between the Syde digital variable and results from the 4 stair-climbing test (4SC)

Time frame
Every 6 months for up to 2 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Centre Hospitalier Universitaire de Liege

Lead sponsor

Centre Hospitalier Régional de la Citadelle

Collaborator

SYSNAV

Collaborator